No Data
Shanghai Henlius Biotech Confirms Qualification of Joint Company Secretary
Shanghai Henlius Biotech Receives Approval for Advanced Cancer Therapy Trial
Express News | Shanghai Henlius Biotech Inc - Application for Phase 1B/2 Clinical Trial of Hlx43- for Injection in- Combination With Hansizhuang Approved by Nmpa
FOSUN PHARMA (02196): HENLIUS has received approval for a clinical trial of HLX4 combined with surufatinib injection for the treatment of patients with advanced/metastatic solid tumors.
FOSUN PHARMA (02196) announced that its holding subsidiary HENLIUS recently received notice from the National Medical Products Administration regarding...
FOSUN PHARMA (600196.SH): The clinical trial application for injectable HLX43 has been approved.
FOSUN PHARMA (600196.SH) announced that its holding subsidiary HENLIUS Biotechnology Co., Ltd...
An alternative "going abroad" for centralized procurement of pharmaceuticals and medical devices? The China-ASEAN regional centralized procurement platform for pharmaceuticals has been launched, and the industry anticipates the birth of the first Order.
① Today, the China-ASEAN pharmaceutical regional procurement platform officially launched, with representatives from Shenzhen Mindray Bio-Medical Electronics, United Imaging Healthcare, SIMCERE PHARMA, and other companies present; ② Although the specific implementation plan is yet to be clarified, the industry believes it is undoubtedly Bullish for domestic pharmaceutical companies; ③ The Southeast Asian pharmaceutical market is growing rapidly, but it relies heavily on imported drugs and medical devices.
